CHEK2 and myeloid neoplasm: In the subset of patients with CHEK2 p.I157T (55%, 44/80), 77% (34/44) had a HM; 56% (19/34) had a myeloid malignancy, 41% (14/34) had a lymphoid malignancy, and 3% (1/34) had both myeloid and lymphoid malignancies (Fig. 2C).